Aravind A Menon1, Rachel K Putman1, Jason L Sanders1, Takuya Hino2, Akinori Hata3, Mizuki Nishino2, Auyon J Ghosh4, Samuel Y Ash1, Ivan O Rosas5, Michael H Cho4, David A Lynch6, George R Washko1, Edwin K Silverman4, Hiroto Hatabu2, Gary M Hunninghake7. 1. Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 2. Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 3. Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Radiology, Osaka University, Osaka, Japan. 4. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA. 5. Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX. 6. Department of Radiology, National Jewish Health, and University of Colorado at Denver Health Sciences Center, Denver, CO. 7. Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: ghunninghake@bwh.harvard.edu.
Abstract
BACKGROUND: Most pulmonary conditions reduce FVC, but studies of patients with combined pulmonary fibrosis and emphysema demonstrate that reductions in FVC are less than expected when these two conditions coexist clinically. RESEARCH QUESTION: Do interstitial lung abnormalities (ILAs), chest CT imaging findings that may suggest an early stage of pulmonary fibrosis in individuals with undiagnosed disease, affect the association between emphysema and FVC? STUDY DESIGN AND METHODS: Measures of ILA and emphysema were available for 9,579 and 5,277 participants from phases 1 (2007-2011) and 2 (2012-2016) of the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study (COPDGene), respectively. ILA were defined by Fleischner Society guidelines. Adjusted linear regression models were used to assess the associations and interactions among ILA, emphysema, measures of spirometry, and lung function. RESULTS: ILA were present in 528 (6%) and 580 (11%) of participants in phases 1 and 2 of COPDGene, respectively. ILA modified the association between emphysema and FVC (P < .0001 for interaction) in both phases. In phase 1, in those without ILA, a 5% increase in emphysema was associated with a reduction in FVC (-110 mL; 95% CI, -121 to -100 mL; P < .0001); however, in those with ILA, it was not (-11 mL; 95% CI, -53 to 31; P = .59). In contrast, no interaction was found between ILA and emphysema on total lung capacity or on diffusing capacity of carbon monoxide. INTERPRETATION: The presence of ILA attenuates the reduction in FVC associated with emphysema.
BACKGROUND: Most pulmonary conditions reduce FVC, but studies of patients with combined pulmonary fibrosis and emphysema demonstrate that reductions in FVC are less than expected when these two conditions coexist clinically. RESEARCH QUESTION: Do interstitial lung abnormalities (ILAs), chest CT imaging findings that may suggest an early stage of pulmonary fibrosis in individuals with undiagnosed disease, affect the association between emphysema and FVC? STUDY DESIGN AND METHODS: Measures of ILA and emphysema were available for 9,579 and 5,277 participants from phases 1 (2007-2011) and 2 (2012-2016) of the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study (COPDGene), respectively. ILA were defined by Fleischner Society guidelines. Adjusted linear regression models were used to assess the associations and interactions among ILA, emphysema, measures of spirometry, and lung function. RESULTS: ILA were present in 528 (6%) and 580 (11%) of participants in phases 1 and 2 of COPDGene, respectively. ILA modified the association between emphysema and FVC (P < .0001 for interaction) in both phases. In phase 1, in those without ILA, a 5% increase in emphysema was associated with a reduction in FVC (-110 mL; 95% CI, -121 to -100 mL; P < .0001); however, in those with ILA, it was not (-11 mL; 95% CI, -53 to 31; P = .59). In contrast, no interaction was found between ILA and emphysema on total lung capacity or on diffusing capacity of carbon monoxide. INTERPRETATION: The presence of ILA attenuates the reduction in FVC associated with emphysema.
Authors: Esther Pompe; Pim A de Jong; David A Lynch; Nikolas Lessmann; Ivana Išgum; Bram van Ginneken; Jan-Willem J Lammers; Firdaus A A Mohamed Hoesein Journal: Eur Respir J Date: 2017-04-19 Impact factor: 16.671
Authors: Rachel K Putman; Gunnar Gudmundsson; Gisli Thor Axelsson; Tomoyuki Hida; Osamu Honda; Tetsuro Araki; Masahiro Yanagawa; Mizuki Nishino; Ezra R Miller; Gudny Eiriksdottir; Elías F Gudmundsson; Noriyuki Tomiyama; Hiroshi Honda; Ivan O Rosas; George R Washko; Michael H Cho; David A Schwartz; Vilmundur Gudnason; Hiroto Hatabu; Gary M Hunninghake Journal: Am J Respir Crit Care Med Date: 2019-07-15 Impact factor: 21.405
Authors: Ezra R Miller; Rachel K Putman; Marina Vivero; Yin Hung; Tetsuro Araki; Mizuki Nishino; George R Washko; Ivan O Rosas; Hiroto Hatabu; Lynette M Sholl; Gary M Hunninghake Journal: Am J Respir Crit Care Med Date: 2018-04-01 Impact factor: 21.405
Authors: Sanja Stanojevic; Brian L Graham; Brendan G Cooper; Bruce R Thompson; Kim W Carter; Richard W Francis; Graham L Hall Journal: Eur Respir J Date: 2017-09-11 Impact factor: 16.671
Authors: David A Lipson; Helen Barnacle; Ruby Birk; Noushin Brealey; Nicholas Locantore; David A Lomas; Andrea Ludwig-Sengpiel; Rajat Mohindra; Maggie Tabberer; Chang-Qing Zhu; Steven J Pascoe Journal: Am J Respir Crit Care Med Date: 2017-08-15 Impact factor: 21.405
Authors: Gary M Hunninghake; Hiroto Hatabu; Yuka Okajima; Wei Gao; Josée Dupuis; Jeanne C Latourelle; Mizuki Nishino; Tetsuro Araki; Oscar E Zazueta; Sila Kurugol; James C Ross; Raúl San José Estépar; Elissa Murphy; Mark P Steele; James E Loyd; Marvin I Schwarz; Tasha E Fingerlin; Ivan O Rosas; George R Washko; George T O'Connor; David A Schwartz Journal: N Engl J Med Date: 2013-05-21 Impact factor: 91.245
Authors: Corrine R Kliment; Tetsuro Araki; Tracy J Doyle; Wei Gao; Josée Dupuis; Jeanne C Latourelle; Oscar E Zazueta; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; James C Ross; Raúl San José Estépar; Alejandro A Diaz; David J Lederer; David A Schwartz; Edwin K Silverman; Ivan O Rosas; George R Washko; George T O'Connor; Hiroto Hatabu; Gary M Hunninghake Journal: BMC Pulm Med Date: 2015-10-29 Impact factor: 3.317